Literature DB >> 32472188

Concatemers to re-investigate the role of α5 in α4β2 nicotinic receptors.

Marie S Prevost1, Hichem Bouchenaki1, Nathalie Barilone1, Marc Gielen2,3, Pierre-Jean Corringer4.   

Abstract

Nicotinic acetylcholine receptors (nAChRs) are pentameric ion channels expressed in the central nervous systems. nAChRs containing the α4, β2 and α5 subunits are specifically involved in addictive processes, but their functional architecture is poorly understood due to the intricacy of assembly of these subunits. Here we constrained the subunit assembly by designing fully concatenated human α4β2 and α4β2α5 receptors and characterized their properties by two-electrodes voltage-clamp electrophysiology in Xenopus oocytes. We found that α5-containing nAChRs are irreversibly blocked by methanethiosulfonate (MTS) reagents through a covalent reaction with a cysteine present only in α5. MTS-block experiments establish that the concatemers are expressed in intact form at the oocyte surface, but that reconstitution of nAChRs from loose subunits show inefficient and highly variable assembly of α5 with α4 and β2. Mutational analysis shows that the concatemers assemble both in clockwise and anticlockwise orientations, and that α5 does not contribute to ACh binding from its principal (+) site. Reinvestigation of suspected α5-ligands such as galantamine show no specific effect on α5-containing concatemers. Analysis of the α5-D398N mutation that is linked to smoking and lung cancer shows no significant effect on the electrophysiological function, suggesting that its effect might arise from alteration of other cellular processes. The concatemeric strategy provides a well-characterized platform for mechanistic analysis and screening of human α5-specific ligands.

Entities:  

Keywords:  Biochemical pharmacology; Concatemers; Ligand-gated ion channels; Neuropharmacology; Nicotinic receptors

Year:  2020        PMID: 32472188     DOI: 10.1007/s00018-020-03558-z

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  40 in total

1.  Knockout of alpha 5 nicotinic acetylcholine receptors subunit alters ethanol-mediated behavioral effects and reward in mice.

Authors:  Anton Dawson; Jennifer T Wolstenholme; Monzurul A Roni; Vera C Campbell; Asti Jackson; Cassandra Slater; Deniz Bagdas; Erika E Perez; Jill C Bettinger; Mariella De Biasi; Michael F Miles; M Imad Damaj
Journal:  Neuropharmacology       Date:  2018-06-23       Impact factor: 5.250

2.  Profound alteration in reward processing due to a human polymorphism in CHRNA5: a role in alcohol dependence and feeding behavior.

Authors:  Morgane Besson; Benoît Forget; Caroline Correia; Rodolphe Blanco; Uwe Maskos
Journal:  Neuropsychopharmacology       Date:  2019-07-09       Impact factor: 7.853

Review 3.  Contribution of Variants in CHRNA5/A3/B4 Gene Cluster on Chromosome 15 to Tobacco Smoking: From Genetic Association to Mechanism.

Authors:  Li Wen; Keran Jiang; Wenji Yuan; Wenyan Cui; Ming D Li
Journal:  Mol Neurobiol       Date:  2014-12-05       Impact factor: 5.590

4.  Nicotine consumption is regulated by a human polymorphism in dopamine neurons.

Authors:  C Morel; L Fattore; S Pons; Y A Hay; F Marti; B Lambolez; M De Biasi; M Lathrop; W Fratta; U Maskos; P Faure
Journal:  Mol Psychiatry       Date:  2013-12-03       Impact factor: 15.992

5.  Mouse striatal dopamine nerve terminals express alpha4alpha5beta2 and two stoichiometric forms of alpha4beta2*-nicotinic acetylcholine receptors.

Authors:  Sharon R Grady; Outi Salminen; J Michael McIntosh; Michael J Marks; Allan C Collins
Journal:  J Mol Neurosci       Date:  2009-08-20       Impact factor: 3.444

6.  The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo.

Authors:  Ramiro Salas; Avi Orr-Urtreger; Ron S Broide; Arthur Beaudet; Richard Paylor; Mariella De Biasi
Journal:  Mol Pharmacol       Date:  2003-05       Impact factor: 4.436

7.  A Human Polymorphism in CHRNA5 Is Linked to Relapse to Nicotine Seeking in Transgenic Rats.

Authors:  Benoit Forget; Petra Scholze; Francina Langa; Carole Morel; Stephanie Pons; Sarah Mondoloni; Morgane Besson; Romain Durand-de Cuttoli; Audrey Hay; Ludovic Tricoire; Bertrand Lambolez; Alexandre Mourot; Philippe Faure; Uwe Maskos
Journal:  Curr Biol       Date:  2018-10-04       Impact factor: 10.834

8.  Alterations in alpha5* nicotinic acetylcholine receptors result in midbrain- and hippocampus-dependent behavioural and neural impairments.

Authors:  Morgane Besson; Stefania Guiducci; Sylvie Granon; Jean-Philippe Guilloux; Bruno Guiard; Christelle Repérant; Philippe Faure; Stéphanie Pons; Giuseppe Cannazza; Michele Zoli; Alain M Gardier; Uwe Maskos
Journal:  Psychopharmacology (Berl)       Date:  2016-07-06       Impact factor: 4.530

9.  Striatal α5 nicotinic receptor subunit regulates dopamine transmission in dorsal striatum.

Authors:  Richard Exley; J Michael McIntosh; Michael J Marks; Uwe Maskos; Stephanie J Cragg
Journal:  J Neurosci       Date:  2012-02-15       Impact factor: 6.167

10.  Habenular α5 nicotinic receptor subunit signalling controls nicotine intake.

Authors:  Christie D Fowler; Qun Lu; Paul M Johnson; Michael J Marks; Paul J Kenny
Journal:  Nature       Date:  2011-01-30       Impact factor: 49.962

View more
  3 in total

1.  Heterologous expression of concatenated nicotinic ACh receptors: Pros and cons of subunit concatenation and recommendations for construct designs.

Authors:  Vivian Wan Yu Liao; Ali Saad Kusay; Thomas Balle; Philip Kiaer Ahring
Journal:  Br J Pharmacol       Date:  2020-08-05       Impact factor: 8.739

Review 2.  The α5 Nicotinic Acetylcholine Receptor Subunit Differentially Modulates α4β2* and α3β4* Receptors.

Authors:  Petra Scholze; Sigismund Huck
Journal:  Front Synaptic Neurosci       Date:  2020-12-03

3.  Structural Insights into the Role of β3 nAChR Subunit in the Activation of Nicotinic Receptors.

Authors:  Petros Giastas; Athanasios Papakyriakou; George Tsafaras; Socrates J Tzartos; Marios Zouridakis
Journal:  Molecules       Date:  2022-07-20       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.